<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">The primary end point of this study was OS. Secondary end points were progression-free survival (PFS), locoregional control (LRC), distant metastasis (DM), and toxicity profiles. According to the 3-year OS of patients with advanced PLSCC treated with CCRT (60%) and those treated with ICT/CCRT (45%) in our daily practice, a sample size of 200 patients was required to achieve 80% power for detecting a 15% difference between the two therapeutic schema by using a 2-sided log-rank test with a type l error rate of 5%.</p>
